AMPLITUDE SURGICAL financials
AMPLITUDE SURGICAL
Country: FR Reporting currency: EUR Latest annual report: 2024-06-30
LEI:
9695006Q1VL1OHK06336 Financial statements
(EUR, as reported — unscaled; 103 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Employee benefits expense | €28.0M | €26.1M |
| Raw materials & consumables used | €20.4M | €18.7M |
| Operating profit (EBIT) | €10.3M | €8.1M |
| Net finance income / (cost) | -€8.6M | -€14.0M |
| Finance costs | €11.5M | €15.6M |
| Income tax expense | €92.0K | €769.0K |
| Profit for the year | €1.5M | €38.5M |
| — attributable to owners | €1.5M | €39.2M |
| — attributable to NCI | €0 | -€718.0K |
| Total comprehensive income | €73.0K | €41.2M |
| Per share | ||
| Basic EPS | €0.03 | €0.82 |
| Diluted EPS | €0.03 | €0.82 |
| Free cash flow / share | €-0.13 | €-0.06 |
| Cash flow statement | ||
| Net cash from operating activities | €4.0M | €8.1M |
| Net cash from investing activities | -€14.4M | €45.5M |
| Purchase of PP&E (capex) | €10.4M | €11.2M |
| Purchase of intangibles | €8.6M | €8.2M |
| Net cash from financing activities | €2.5M | -€37.4M |
| Dividends paid | €0 | €0 |
| Proceeds from borrowings | €9.4M | €11.9M |
| Repayments of borrowings | €9.9M | €48.8M |
| Net change in cash | -€7.9M | €16.2M |
| Balance sheet | ||
| Total assets | €279.3M | €266.0M |
| Non-current assets | €184.6M | €170.6M |
| Intangible assets & goodwill | €98.8M | €95.6M |
| Current assets | €94.7M | €95.5M |
| Inventories | €43.3M | €38.0M |
| Trade & other receivables | €21.1M | €18.9M |
| Cash & equivalents | €29.1M | €37.2M |
| Total equity | €95.8M | €95.8M |
| Non-controlling interests | €0 | €0 |
| Non-current liabilities | €136.5M | €128.9M |
| Current liabilities | €46.9M | €41.3M |
| Trade & other payables | €28.8M | €29.2M |
| Deferred tax liabilities | €2.1M | €1.7M |
| Derived metrics | ||
| Free cash flow | -€6.3M | -€3.1M |
| Operating margin | 9.7% | 8.0% |
| Net margin | 1.4% | 38.5% |
| Return on equity | 1.6% | 40.2% |
| Cash conversion ratio | 2.65× | 0.21× |
| Capex coverage | 0.39× | 0.72× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | -€274.0K | €2.8M |
| Adjusted Weighted Average Shares | 48.0M | 48.0M |
| Adjustments For Decrease Increase In Inventories | -€5.4M | €3.7M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€1.4M | €2.6M |
| Adjustments For Income Tax Expense | €92.0K | €769.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€1.1M | €1.4M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €119.0K | -€51.4M |
| Adjustments For Sharebased Payments | €0 | €0 |
| Bank Overdrafts Classified As Cash Equivalents | €6.0K | €26.0K |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €29.1M | €37.2M |
| Cash Flows From Used In Operations Before Changes In Working Capital | €12.9M | €1.2M |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | -€636.0K |
| Comprehensive Income Attributable To Owners of Parent | €73.0K | €41.8M |
| Cost of Merchandise Sold | €11.2M | €11.8M |
| Current Provisions | €612.0K | €281.0K |
| Current Tax Assets Current | €1.2M | €1.4M |
| Current Tax Liabilities Current | €404.0K | €594.0K |
| Deferred Tax Assets | €6.6M | €5.1M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€194.0K | -€38.0K |
| Equity and Liabilities | €279.3M | €266.0M |
| Finance Income | €2.9M | €1.6M |
| Gains Losses On Disposals of Noncurrent Assets | -€119.0K | €59.0K |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €0 | €0 |
| Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income | -€169.0K | €120.0K |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | €0 | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €1.1M | €943.0K |
| Increase Decrease In Number of Ordinary Shares Issued | 0.0M | 0.0M |
| Increase Decrease In Working Capital | €7.9M | -€7.9M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | €0 | €0 |
| Increase Decrease Through Disposal of Subsidiary | €0 | €2.2M |
| Increase Decrease Through Sharebased Payment Transactions | €0 | €0 |
| Increase Decrease Through Transfers and Other Changes Equity | -€5.0K | -€177.0K |
| Increase Decrease Through Treasury Share Transactions | -€59.0K | €0 |
| Intangible Assets Other Than Goodwill | €37.3M | €31.8M |
| Interest Expense | €10.1M | €11.1M |
| Issue of Equity | €0 | €0 |
| Issued Capital | €480.0K | €480.0K |
| Liabilities Included In Disposal Groups Classified As Held For Sale | €0 | €0 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | €0 | €0 |
| Noncurrent Derivative Financial Liabilities | €0 | €0 |
| Noncurrent Provisions For Employee Benefits | €524.0K | €537.0K |
| Number of Shares Issued | 47.8M | 47.8M |
| Other Comprehensive Income Before Tax Cash Flow Hedges | -€675.0K | €479.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €0 | €0 |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | -€507.0K | €359.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€949.0K | €2.3M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €0 | €0 |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€1.5M | €2.7M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €0 | €0 |
| Other Finance Cost | €1.4M | €4.6M |
| Other Finance Income | €2.9M | €1.6M |
| Other Longterm Provisions | €14.2M | €14.7M |
| Other Noncurrent Financial Assets | €465.0K | €709.0K |
| Other Noncurrent Liabilities | €17.7M | €16.7M |
| Other Work Performed By Entity and Capitalised | €9.7M | €9.8M |
| Profit Loss From Discontinued Operations | €0 | €45.3M |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€52.6M | -€93.4M |
| Retained Earnings Profit Loss For Reporting Period | €1.5M | €39.2M |
| Revenue From Contracts With Customers | €106.0M | €100.2M |
| Share Premium | €146.7M | €146.7M |
| Tax Expense Other Than Income Tax Expense | €962.0K | €920.0K |
| Weighted Average Shares | 48.0M | 48.0M |
Methodology
Every line item above is a fact tagged in AMPLITUDE SURGICAL's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.